摘要
研究气血康口服液耐缺氧作用。取60只SPF级昆明小鼠,随机分为6组(n=10)。除正常对照组外,每天灌胃给予阳性对照组1(盐酸地尔硫卓),阳性对照组2(红景天口服液)气血康口服液低、中、高3个剂量(2.5、5.0、10.0mL/kg BW),连续30d。经常压单次缺氧暴露试验,记录小鼠缺氧耐受死亡时间。结果显示,与正常对照组相比,阳性组小鼠存活时间均显著延长(P<0.01)。与正常对照组相比,中、高剂量气血康口服液组存活时间均显著延长(P<0.05);与阳性组相比,气血康口服液高剂量组存活时间无显著差异(P>0.05)。研究发现,小鼠耐缺氧能力与气血康口服液剂量的增加呈线性正相关,高剂量耐受缺氧能力与阳性药相当,中剂量耐受缺氧能力与盐酸地尔硫卓相当。本试验中气血康口服液中剂量为有效剂量。
Study the anti hypoxia effect of Qixuekang oral liquid.Sixty SPF grade Kunming mice were randomly divided into 6 groups(n=10).In addition to the normal control group,positive control group 1(diltiazem hydrochloride)and positive control group 2(Hongjingtian oral liquid)were given three doses(2.5,5.0,and 10.0 mL/kg BW)of Qixuekang oral liquid by gavage every day for 30 consecutive days.Regularly conduct a single hypoxic exposure test and record the time of mouse hypoxia tolerance death.The results showed that compared with the normal control group,the survival time of the positive group mice was significantly prolonged(P<0.01).Compared with the normal control group,the survival time of the medium and high-dose Qixuekang oral liquid groups was significantly prolonged(P<0.05);Compared with the positive group,there was no significant difference in survival time between the high-dose group of Qixuekang oral liquid(P>0.05).Research has found that there is a linear positive correlation between the hypoxia tolerance of mice and the increase in dosage of Qixuekang oral liquid.The tolerance to hypoxia at high doses is equivalent to that of positive drugs,while the tolerance to hypoxia at medium doses is equivalent to that of diltiazem hydrochloride.The middle dose of Qixuekang oral liquid in this experiment is the effective dose.
作者
李惠娟
佘振南
韦济迁
李辉
陶尚贵
顾润琦
杨归
郝静超
Li Huijuan;She Zhennan;Wei Jiqian;Li Hui;Tao Shanggui;Gu Runqi;Yang Gui;HaoJingchao(Yunnan Baiyao Group Traditional Chinese Medicine Resources Co.,Ltd.,Kunming,Yunnan 650500;School of Pharmaceutical Science,Kunming Medical University,Kunming,Yunnan 650500;Yunnan Baiyao Group Wenshan Qihua Co.,Ltd.,Wenshan,Yunnan 663099)
出处
《科技与健康》
2023年第15期1-4,共4页
Technology and Health
基金
云南省基础研究专项面上项目(202101AT070170,202201AT070134)。
关键词
气血康口服液
常压单次缺氧暴露试验
存活时间
Qixuekang oral liquid
atmospheric pressure single hypoxia exposure test
survival time
